Abstract:SUMMARY Many potential drug candidates pose potent anti-tumor activities, but they have either low solubility or high toxicities. We identified a novel Wnt pathway inhibitor, which displays anti-tumor activities through inhibition of tumor cell proliferations. However, it has low solubility and high toxicity. In our current study, we prepared RH40 micelles to encapsulate the drug, in order to improve its solubility and reduce its toxicity in animals. The micelle formulation could be administered intravenously and improve the drug distribution in tumor tissue/cells. Potentially, this strategy may allow us to overcome the hurdle of low solubility of drugs in order to improve their anti-tumor efficacy and reduce non-target toxicity. INTRODUCTION We have identified a novel compound CL010, which is an inhibitor targeting at the Wnt pathway. It was discovered through screening efforts using cell models for inhibiting signaling Wnt pathway. Our in vitro study indicated that it is highly potent in inhibiting growth and proliferation of cancer cells overexpressing of RSPO2/3. A few in vivo primary tumor models were established in order to test in vivo anti-tumor activities of CL010. However, CL010 was found to have very poor water solubility, which would restrict investigation of its dose responses in vivo. Therefore, improving the aqueous solubility of CL010 is essential before we can initiate in vivo studies to test its efficacy in animal models via different dosing schemes. In addition, the compound CL010 appeared to be toxic to mice when administered in vivo. Thus, the current study aims to improve the compound solubility and reduce its toxicity through micelle technology. EXPERIMENTAL METHODS 1. Preparation of micelle formulations containing the compound CL010: CL010 were dissolved in tert-butyl alcohol and mixed with water containing 20% cremophor RH40 and 5% mannitol. The solvents were removed by lyophilization. The lyophilized powder was then rehydrated with water. The anti-wnt compounds in micelles could increase its concentration to 3 mg/ml. This is a big improvement over its maximum solubility in water. (Table 1. Size distribution of the micelle) 2. Animal model setup: We select two gastric and one liver primary tumor samples, cut human tumor samples into 1 mm × 1 mm × 1 mm fragments, implant in 6-8 weeks old nude mice, start treatment when tumors reach 200 mm (length × width × width) / 2, dose mice via IV, and PO, and measure tumor size and bodyweight twice a week. RESULTS AND DISCUSSION We used the micelle formulation to prepare the CL010 compounds to dose animal via IV (Figure 1). The results show that there is difference in tumor sizes in the group treated with micelle-formulated CL010 compound, while the bodyweight of the treated mice were not reduced. Therefore, above studies demonstrated that micelle formulation improved the solubility of the compound CL010, and reduced its toxic effects on mice. Table1. Size distribution of the micelle with CL010 Figure1. In vivo testing of CL010 packed in micelle formulation on the Gastric #1 model. CONCLUSION Using an anti-Wnt pathway inhibitor, we have demonstrated that micelle formulations containing compound CL010 had improved its solubility. In addition, the micelle formation appears to reduce its toxic effects in vivo when given via IV. Therefore, we conclude that micelle formulation strategy may facilitate antitumor therapy by overcoming the hurdle of low solubility of drugs in order to improve their antitumor efficacy and reduce non-target toxicity. Currently, we are performing additional studies to search for better compositions of micelle formation, and to provide more solid in vivo data to provide evidence to support this strategy. REFERENCES 1. Genevieve. J; Robert, H.M. J Control Release 2010, 143, 2-12. 2. Ho-Chul. S; Adam W. G. Mol Pharmaceutics 2011, 8, 1257–1265. 200 60

A novel core-shell lipid nanoparticle for improving oral administration of water soluble chemotherapeutic agents: inhibited intestinal hydrolysis and enhanced lymphatic absorption

Lactone Stabilized by Crosslinked Cyclodextrin Metal-Organic Frameworks to Improve Local Bioavailability of Topotecan in Lung Cancer

Core-crosslinked Nanomicelles Based on Crosslinkable Prodrug and Surfactants for Reduction Responsive Delivery of Camptothecin and Improved Anticancer Efficacy.

Hydrogen-Bonded Tannic Acid-Based Anticancer Nanoparticle for Enhancement of Oral Chemotherapy

Redox Sensitive Lipid-Camptothecin Conjugate Encapsulated Solid Lipid Nanoparticles for Oral Delivery.

Nanostructured Lipid Carriers As a Novel Oral Delivery System for Triptolide: Induced Changes in Pharmacokinetics Profile Associated with Reduced Toxicity in Male Rats

Nanomicelle Based Peroral Delivery System for Enhanced Absorption and Sustained Release of 10-Hydrocamptothecin

Enabling oral novel Taxanes-based Chemotherapy with Lipophilic prodrug Self-nanoemulsifying drug delivery system

Sodium Dodecyl Sulfate-Modified Doxorubicin-Loaded Chitosan-Lipid Nanocarrier with Multi Polysaccharide-Lecithin Nanoarchitecture for Augmented Bioavailability and Stability of Oral Administration in Vitro and in Vivo.

In Vivo Anti-Tumor Efficacy Study of a Novel Wnt pathway Inhibitor Packed in RH 40 Micelles

Enhanced Oral Delivery Of Paclitaxel Using Acetylcysteine Functionalized Chitosan-Vitamin E Succinate Nanomicelles Based On A Mucus Bioadhesion And Penetration Mechanism

Preparation, Characterization, and Anti-Tumor Property of Podophyllotoxin-Loaded Solid Lipid Nanoparticles

Formulation, Pharmacokinetic Evaluation and Cytotoxicity of an Enhanced- penetration Paclitaxel Nanosuspension.

Multi-functional Chitosan Polymeric Micelles As Oral Paclitaxel Delivery Systems for Enhanced Bioavailability and Anti-Tumor Efficacy.

Mechanisms of Chitosan-Coated Poly(Lactic-Co-Glycolic Acid) Nanoparticles for Improving Oral Absorption of 7-Ethyl-10-hydroxycamptothecin

The Preparation, Characterization, and Pharmacokinetic Studies of Chitosan Nanoparticles Loaded with Paclitaxel/Dimethyl-Beta-Cyclodextrin Inclusion Complexes

Improving the Oral Delivery Efficiency of Anticancer Drugs by Chitosan Coated Polycaprolactone-Grafted Hyaluronic Acid Nanoparticles.

Topotecan-loaded thermosensitive nanocargo for tumor therapy: In vitro and in vivo analyses

Liposomes Co-Modified with Cholesterol Anchored Cleavable PEG and Octaarginines for Tumor Targeted Drug Delivery

Improved Oral Bioavailability, Therapeutic Efficacy, and Reduced Toxicity of Tamoxifen-Loaded Liquid Crystalline Nanoparticles

A Novel Camptothecin Derivative Incorporated in Nano-Carrier Induced Distinguished Improvement in Solubility, Stability and Anti-tumor Activity Both In Vitro and In Vivo